The global vascular access devices market, valued at US$5.60 billion in 2023, is forecasted to grow at a robust CAGR of 7.1%, ...

Q4 2024 Earnings Call Transcript February 20, 2025 Prothena Corporation plc misses on earnings expectations. Reported EPS is ...

PRTA posts a wider-than-expected fourth-quarter loss. However, it reports encouraging pipeline progress for the quarter.

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™for all indicationsmatching the reference product ...

Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism ... by treating low disease burden patients in the front-line ...

We recently compiled a list of the 10 Best Non-Tech Stocks to Buy Now for Long Term. In this article, we are going to take a ...

Panelists discuss how CARTITUDE-4 demonstrated superior progression-free survival and overall response rates with ...

Panelists discuss how to address practical challenges in delivering chimeric antigen receptor (CAR) T cell therapy, including patient selection, bridging therapy, manufacturing delays, access barriers ...